Edison Investment Research - Univo Pharmaceuticals (UNIVO) Univo Pharmaceuticals Ltd - Controlling the value chain

Report

Edison Investment Research

Kate Heseltine

Univo Pharmaceuticals Ltd - Controlling the value chain

UNIVO is a vertically integrated Israeli medical cannabis company. It claims that full control of the value chain, from cultivation to distribution, allows for the maintenance of high-quality product and service. This is evidenced by UNIVO’s expanding share of the growing Israeli medical cannabis market. In addition, it has internationally certified facilities (IMC-GMP) and is poised to commence exports from Israel. Key to UNIVO’s continued progress will be the development of innovative medical cannabis-based products at its 1,600 sq ft research facility and the cooperation agreement with Rambam Hospital. UNIVO has four patents for medical indications granted in Israel.

19/10/2021 2 EN

Underlying

Univo Pharmaceuticals

D-Pharm Ltd. is an Israel-based drug-development company. The Company is focused on developing drugs for the treatment of central nervous system (CNS) conditions. Its area of interest is in developing medicine for degenerative and age-related disorders. The Company's product portfolio includes three clinical Phase II drug-candidates: THR-18 for thrombolysis, to restore blood flow to the brain, heart or lungs, which completed clinical Phase I and Phase II study in acute stroke patients receiving tPA; DP-VPA for the treatment of epilepsy, migraine and manic depression, which has completed a Phase II study in patients with complex partial epilepsy, and DP-b99, which contains calcium, zinc and copper ions and is used for the protection of cells under stress in acute pancreatitis. The Company's two technology platforms Membrane Activated Chelator and Regulated Activation of Prodrug use lipid moieties conjugated onto actives such as metal ion chelators or drugs for site specific activation.

See profile

IL0010935588 Tel-Aviv Stock Exchange Israel

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Kate Heseltine

Other Reports on these Companies

Edison Investment Research

Univo Pharmaceuticals Ltd - Controlling the value chain

October 19, 2021 October 19, 2021 2 EN

BusinessWire

Former Israeli Prime Minister Ehud Olmert Joins Medical Cannabis Company Univo

ASHKELON, Israel--(BUSINESS WIRE)-- (TASE: UNVO.TA) (), the one-stop-shop solution for medical cannabis from seed to market, announces today that former Israeli Prime Minister Ehud Olmert is joining the company as an investor and professional advisor. This press release features multimedia. View the full release here: (Photo: Ehud Olmert) This news follows recent Univo achievements since the beginning of 2019, such as the securing of all four licenses for the cultivation, research and development, production, and dist...

April 16, 2019 April 16, 2019 1 EN

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Pedro Fonseca

Pedro Fonseca

Baillie Gifford US Growth Trust - A unique high-growth strategy meriting support

Baillie Gifford US Growth Trust (USA) invests in exceptional US businesses with the potential to grow substantially faster than the market and deliver above-market returns. Such businesses tend to operate at the cutting edge of technology-led change and USA has exposure to companies focused on AI, space travel and online services. This note reiterates USA’s unique investment proposition and scrutinises a recent proposal from Saba, a US hedge fund manager, aimed at ousting USA’s board and replacing its investment managers. Saba currently owns less than 28% of USA shares in issue. The trust’s bo...

January 10, 2025 January 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

Greggs - More challenging environment in H224

Greggs has reported that FY24 profit is in line with management’s expectation despite the more challenging environment and slowing sales growth through H224. The more challenging market means that management is more cautious about the outlook for H125 than previously. With space expansion and recovery of cost inflation, it expects to deliver profit growth in FY25 albeit lower than previously anticipated. We have reduced our FY25 profit before tax estimate by c 2%.

January 9, 2025 January 9, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Univo Pharmaceuticals Ltd - Controlling the value chain

Univo Pharmaceuticals Ltd - Controlling the value chain

Former Israeli Prime Minister Ehud Olmert Joins Medical Cannabis Company Univo

Topps Tiles - Accelerating growth through Q125

Baillie Gifford US Growth Trust - A unique high-growth strategy meriting support

Greggs - More challenging environment in H224

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe